Olaparib and, in some countries, talazoparib, are indicated as single agents for previously treated breast cancer patients who have HER2-negative or HR-positive locally advanced or metastatic breast cancer with germline BRCA1/2 mutations, or as first-line therapy when patients are not suitable for standard therapies. Here, ERBB2 is linked to breast cancer.